Overview

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

Status:
Completed
Trial end date:
2009-08-13
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, double-blinded study is to test the safety of GSK1265744 and how well it works on reducing the amount of HIV in the blood. It will also look at how people react to and how a human body uses GSK1265744. This study will compare the effects of GSK1265744 and placebo. The study will consist of 1 or 2 parts to look at doses of GSK1265744. About 8 people will take part in Part 1 of the study receiving dose A. If additional dosing information is needed after Part 1, about 6 people will take part in Part 2 of the study receiving dose B.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
ViiV Healthcare
Collaborators:
GlaxoSmithKline
Shionogi
Treatments:
Cabotegravir